Mabpharm Limited 

Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for allergic diseases, cancers, and autoimmune diseases in China. Its products under the Phase III clinical trial include CMAB007, a recombinant humanized anti-IgE monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for moderate to severe active rheumatoid arthritis; and CMAB807 for osteoporosis indications. The company is also developing CMAB819 that is in Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X for the treatment of tumor bone metastasis; and CMAB809 that is in Phase I clinical trial for the treatment of HER2 overexpressing breast cancer and metastatic gastric cancer. In addition, its products under the pre-clinical stage include CMAB810 for the treatment of breast cancer; CMAB816 for the treatment of periodic fever syndrome, lung cancer, and systemic juvenile idiopathic arthritis; CMAB017 for the treatment of KRAS wild-type colorectal cancer; CMAB015, a biosimilar candidate for secukinumab to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a biosimilar candidate for mepolizumab, for the treatment of asthma and eosinophilic granulomatous polyangiitis; and CMAB022 for the treatment of inflammatory diseases. The company also involved in research and development, technical consulting, technology transfer, and technical services of biological products, diagnostic reagents, chemical biological reagents, and drugs. The company was incorporated in 2018 and is headquartered in Taizhou, the People's Republic of China.